Ginkgo Bioworks (NYSE:DNA) Rating Lowered to Sell at Wall Street Zen

Ginkgo Bioworks (NYSE:DNA) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other equities research analysts also recently weighed in on DNA. Weiss Ratings reissued a “sell (d-)” rating on shares of Ginkgo Bioworks in a report on Wednesday, October 8th. BTIG Research boosted their target price on shares of Ginkgo Bioworks from $6.00 to $9.00 and gave the stock a “sell” rating in a report on Monday, August 25th. Finally, Cowen reissued a “buy” rating on shares of Ginkgo Bioworks in a research note on Friday, August 8th. One investment analyst has rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $9.00.

Ginkgo Bioworks Stock Performance

Shares of NYSE DNA opened at $9.00 on Friday. Ginkgo Bioworks has a 1 year low of $5.00 and a 1 year high of $17.58. The firm has a market cap of $532.50 million, a P/E ratio of -1.44 and a beta of 1.53. The stock has a fifty day moving average price of $12.60 and a two-hundred day moving average price of $10.93.

Ginkgo Bioworks (NYSE:DNA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($1.45) EPS for the quarter, missing analysts’ consensus estimates of ($1.24) by ($0.21). Ginkgo Bioworks had a negative return on equity of 49.23% and a negative net margin of 188.00%.The firm had revenue of $38.84 million during the quarter, compared to the consensus estimate of $38.95 million. Ginkgo Bioworks has set its FY 2025 guidance at EPS. On average, research analysts predict that Ginkgo Bioworks will post -10.02 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Ginkgo Bioworks news, insider Steven P. Coen sold 5,609 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $15.00, for a total value of $84,135.00. Following the completion of the transaction, the insider directly owned 5,503 shares in the company, valued at $82,545. This trade represents a 50.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 9.72% of the company’s stock.

Hedge Funds Weigh In On Ginkgo Bioworks

Institutional investors and hedge funds have recently modified their holdings of the stock. Raymond James Financial Inc. acquired a new position in shares of Ginkgo Bioworks during the 2nd quarter worth $29,000. Strs Ohio bought a new stake in Ginkgo Bioworks in the third quarter worth $44,000. Ameritas Investment Partners Inc. acquired a new position in Ginkgo Bioworks during the second quarter worth $45,000. State of Wyoming bought a new position in Ginkgo Bioworks during the third quarter valued at about $74,000. Finally, US Bancorp DE lifted its position in shares of Ginkgo Bioworks by 43.5% in the first quarter. US Bancorp DE now owns 6,302 shares of the company’s stock worth $36,000 after buying an additional 1,911 shares during the last quarter. 78.63% of the stock is currently owned by hedge funds and other institutional investors.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.